Is Cefepime Appropriate for E. coli UTI?
Yes, cefepime is an appropriate and FDA-approved treatment option for urinary tract infections caused by E. coli, including both uncomplicated and complicated UTIs as well as pyelonephritis. 1
FDA-Approved Indication
Cefepime is specifically FDA-approved for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by E. coli. 1 The drug label explicitly lists E. coli as a covered pathogen for both mild-to-moderate and severe UTI presentations. 1
Guideline-Supported Use
The 2024 European Association of Urology guidelines include cefepime as a recommended empirical parenteral antimicrobial for uncomplicated pyelonephritis requiring hospitalization, listing it as an extended-spectrum cephalosporin option. 2 The recommended dosing is 1-2 g twice daily, with the higher dose preferred despite lower doses being studied. 2
Dosing Based on Severity
For severe UTIs or pyelonephritis caused by E. coli or K. pneumoniae: Use 2 g IV every 12 hours for 10 days. 1
For mild-to-moderate UTIs caused by E. coli, K. pneumoniae, or P. mirabilis: Use 0.5-1 g IV every 12 hours for 7-10 days. 1
Evidence for ESBL-Producing E. coli
Cefepime demonstrates comparable efficacy to carbapenems for ESBL-producing E. coli UTIs when in vitro susceptibility is confirmed. 3, 4 A 2023 retrospective study showed no difference in clinical cure between cefepime and carbapenems (96.9% vs 95.7%, P=0.999) for ESBL-producing Enterobacterales UTIs. 3 Similarly, a 2018 study found zero clinical or microbiological failures with cefepime for ESBL-producing Enterobacteriaceae UTIs. 4
Critical Caveat: Susceptibility Testing Required
However, a major caveat exists: A 2017 randomized controlled trial was stopped early for the cefepime arm due to unexpectedly high treatment failure (only 33.3% efficacy) in febrile nosocomial UTI caused by ESBL-producing E. coli, despite in vitro susceptibility. 5 This contrasted sharply with piperacillin-tazobactam (94% efficacy) and ertapenem (94% efficacy) in the same trial. 5
Therefore, while cefepime is FDA-approved and guideline-supported for E. coli UTIs, you must:
- Confirm in vitro susceptibility before use 1
- Consider local resistance patterns 2
- Exercise particular caution with ESBL-producing strains in nosocomial/healthcare-associated infections 5
- Consider alternative agents (piperacillin-tazobactam or carbapenems) for ESBL-producing E. coli in febrile UTI/pyelonephritis 5
Resistance Trends
Be aware that E. coli resistance to cefepime has been increasing over time, with one study showing significant increases in resistance rates from 2014 to 2018. 6 This underscores the importance of obtaining culture and susceptibility data whenever possible. 1